Atlas Trials

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Clinical trial NCT05918328 · RECRUITING

Trial details

NCT number
NCT05918328
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHER2-positive Breast Cancer
Start date
2023-05-03
Primary completion
2025-12-01
Enrollment
610

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.